NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
78.99 -0.01 (-0.01%) GOLD FUTURES
2,311.30 +0.30 (+0.01%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
46,957.77 +1,157.77 (+2.53%)
Dynavax Technologies Corporation (0IDA.L)
| Previous close | 11.82 |
| Open | 12.01 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 11.54 - 12.01 |
| 52-week range | 9.50 - 15.15 |
| Volume | |
| Avg. volume | 1,118 |
| Market cap | 2.447M |
| Beta (5Y monthly) | 1.28 |
| PE ratio (TTM) | 0.15 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the U.S. financial markets close.
- PR Newswire
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at TD Cowen's 44th Annual Health Care Conference on Monday, March 4 at 10:30 a.m. ET.
- PR Newswire
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023.
